Amalgamated Financial’s Myriad Genetics MYGN Stock Holding History

Amalgamated Financial’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$901K	Buy	+35,745	New	+$915K	0.01%	1219

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Amalgamated Financial's MYGN Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Myriad Genetics (MYGN) in Q1 2022: 35,745 shares worth $901K. The stake represents 0.01% of the portfolio and ranks #1219 among its holdings.

205 funds tracked by Wall St. Rank hold MYGN as of Q1 2022.

Amalgamated Financial held 35,745 shares of Myriad Genetics worth $901K as of Q1 2022.
Myriad Genetics was a new Amalgamated Financial position in Q1 2022.
Myriad Genetics made up 0.01% of Amalgamated Financial's portfolio in Q1 2022, its #1219 holding.
205 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.